Fluzoparib
- Generic Name
- Fluzoparib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F4N6O2
- CAS Number
- 1358715-18-0
- Unique Ingredient Identifier
- TWF0ML1CK8
- Background
Fluzoparib is under investigation in clinical trial NCT03863860 (A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients).
- Indication
⑴适用于既往经过二线及以上化疗的伴有胚系BRCA突变(gBRCAm)的铂敏感复发性卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。⑵适用于铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 105
- Registration Number
- NCT06735326
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Zhimin Shao
- Target Recruit Count
- 307
- Registration Number
- NCT06612814
- Locations
- 🇨🇳
breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 260
- Registration Number
- NCT06561022
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06552858
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 48
- Registration Number
- NCT06541314
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT06539091
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 33
- Registration Number
- NCT06516445
- Locations
- 🇨🇳
Tongji hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 117
- Registration Number
- NCT06413992
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Target Recruit Count
- 200
- Registration Number
- NCT06255392
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT06161272
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Guangxi Medical University., Nanning, Guangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.